



Market Announcement

27 August 2018

Resonance Health Limited (ASX: RHT) – Trading Halt

Description

The securities of Resonance Health Limited ('RHT') will be placed in trading halt at the request of RHT, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Wednesday, 29 August 2018 or when the announcement is released to the market.

Issued by

Ben Secrett

Principal Adviser, Listings Compliance (Perth)

25 August 2018

ASX Limited
Level 40 Central Park
152 - 158 St Georges Terrace
PERTH WA 6000

Via email - tradinghaltsperth@asx.com.au & Shannon.nicholson@asx.com.au

Dear Shannon,

Trading Halt


Pursuant to ASX Listing Rule 17.1, Resonance Health Limited (ASX Code: RHT) ("Resonance" or "Company") requests that an immediate trading halt be put on its securities, pending an ASX announcement.

In accordance with Listing Rule 17.1, the Company advises:

- a) the reason for the trading halt is to provide additional information in relation to the Company's announcement on 23 August 2018, "Resonance Health announces two new clinical trial contracts".
- b) the trading halt is expected to last until the Company releases clarification of the announcement.
- c) the Company is not aware of any reason why the trading halt should not be granted or of any other information necessary to inform the market about the trading halt.

Please call the undersigned if you have any queries in relation to this request.

Yours faithfully



Agha Shahzad Pervez
Company Secretary